Lupus Clinical Trials in Baltimore, MD

22 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	<1 mi
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)	—	Hospital for Special Surgery, New York	<1 mi
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN	—	GlaxoSmithKline	<1 mi
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).	Phase 3	Novartis Pharmaceuticals	<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)	Phase 1	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)	—	Ampel BioSolutions, LLC	<1 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V	Phase 2	Novartis Pharmaceuticals	<1 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants	—	Bristol-Myers Squibb	32 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus	Phase 3	UCB Biopharma SRL	32 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants	Phase 3	AstraZeneca	34 mi
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires	—	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	34 mi
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus	Phase 1/2	National Heart, Lung, and Blood Institute (NHLBI)	34 mi
Deciphering the Genetic Architecture of Autoimmune Diseases	—	National Human Genome Research Institute (NHGRI)	34 mi
Study of Systemic Lupus Erythematosus	—	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	34 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE	Phase 1/2	AstraZeneca	34 mi
Patient-Centered Assessment of Symptoms and Outcomes	—	National Center for Complementary and Integrative Health (NCCIH)	34 mi
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD	Phase 2	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	34 mi
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis	Phase 1	National Institute of Allergy and Infectious Diseases (NIAID)	34 mi
Research Accelerated by You Lupus Registry	—	Lupus Foundation of America	36 mi
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders	Phase 1/2	Cartesian Therapeutics	36 mi
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions	—	Children's National Research Institute	36 mi
Lupus Landmark Study: A Prospective Registry and Biorepository	—	Lupus Research Alliance	36 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.